Anne Douar, Chief Development Officer of Vivet Therapeutics, will give a presentation (“Investigating Assessment of AAV Safety & Toxicity” Session MANUFACTURING – Ensuring Gene Therapy Safety & Quality) during the 4th Annual Gene Therapy for Rare Disorders Europe virtual conference on Oct. 28th at 1.30pm UTC.
